{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:17Z","timestamp":1787026517423,"version":"build-2736575974"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["M2021080"],"award-info":[{"award-number":["M2021080"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Inherited autosomal dominant gain-of-function (GOF) mutations of signal transducer and activator of transcription 1 (STAT1) cause a wide range of symptoms affecting multiple systems, including chronic mucocutaneous candidiasis (CMC), infections, and autoimmune disorders. We describe a rare case of STAT1 mutation with recurrent CMC, lung infections, and anemia. According to the whole-exome sequencing (WES), the patient was genetically mutated in STAT1 GOF (c.854A&amp;gt;G, p.Q285R), and bone marrow biopsy suggested pure red cell aplasia (PRCA). As a functional verification, STAT1 levels and phosphorylation (p-STAT1) of peripheral blood mononuclear cells (PBMCs) following IFN-\u03b3 stimulation in STAT1 GOF patient was higher than in the healthy control. Combination therapy of blood transfusion, antimicrobials, intravenous immunoglobulin, methylprednisolone, and the Janus Kinase (JAK) specific inhibitor ruxolitinib was used during treatment of patients. The patient also received a hematopoietic stem cell transplant (HSCT) to help with infections and anemia. This is the first reported case of STAT1 GOF disease complicated with PRCA. This complication might be attributed to immune disorders caused by STAT1 GOF. Furthermore, ruxolitinib may be a viable therapeutic option before HSCT to improve disease management.<\/jats:p>","DOI":"10.3389\/fimmu.2022.928213","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T01:17:36Z","timestamp":1661735856000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Case report: A STAT1 gain-of-function mutation causes a syndrome of combined immunodeficiency, autoimmunity and pure red cell aplasia"],"prefix":"10.3389","volume":"13","author":[{"given":"Yifan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenli","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiguo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1100102","article-title":"STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis","volume":"365","author":"van de Veerdonk","year":"2011","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00847-x","article-title":"Human STAT1 gain-of-Function heterozygous mutations: Chronic mucocutaneous candidiasis and type I interferonopathy","volume":"40","author":"Okada","year":"2020","journal-title":"J Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10875-015-0214-9","article-title":"The extended clinical phenotype of 26 patients with chronic mucocutaneous candidiasis due to gain-of-Function mutations in STAT1","volume":"36","author":"Depner","year":"2016","journal-title":"J Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01433","article-title":"STAT1 gain-of-Function mutations cause high total STAT1 levels with normal dephosphorylation","volume":"10","author":"Zimmerman","year":"2019","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679902","article-title":"Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype","volume":"127","author":"Toubiana","year":"2016","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.02.013","article-title":"Prostaglandin E2 suppresses antifungal immunity by inhibiting interferon regulatory factor 4 function and interleukin-17 expression in T cells","volume":"36","author":"Valdez","year":"2012","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401467","article-title":"Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody","volume":"193","author":"Yamazaki","year":"2014","journal-title":"J Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.09.011","article-title":"Molecular mechanisms of mucocutaneous immunity against candida and staphylococcus species","volume":"130","author":"Mar\u00f3di","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.654406","article-title":"Clinical relevance of gain- and loss-of-Function germline mutations in STAT1: A systematic review","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201445344","article-title":"Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC)","volume":"45","author":"Zheng","year":"2015","journal-title":"Eur J Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.jaci.2016.11.022","article-title":"Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation","volume":"139","author":"Weinacht","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw020","article-title":"Ruxolitinib induces interleukin 17 and ameliorates chronic mucocutaneous candidiasis caused by STAT1 gain-of-Function mutation","volume":"62","author":"M\u00f6ssner","year":"2016","journal-title":"Clin Infect Dis an Off Publ Infect Dis Soc America"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.12.1867","article-title":"Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation","volume":"135","author":"Higgins","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10875-018-0519-6","article-title":"Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-Function mutation","volume":"38","author":"Bloomfield","year":"2018","journal-title":"J Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00943-y","article-title":"Stepwise reversal of immune dysregulation due to STAT1 gain-of-Function mutation following ruxolitinib bridge therapy and transplantation","volume":"41","author":"Kayaoglu","year":"2021","journal-title":"J Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0312-3","article-title":"Severe early-onset combined immunodeficiency due to heterozygous gain-of-Function mutations in STAT1","volume":"36","author":"Baris","year":"2016","journal-title":"J Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2017.03.049","article-title":"Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations","volume":"141","author":"Leiding","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.medj.2021.12.003","article-title":"JAK inhibition in a patient with a STAT1 gain-of-function variant reveals STAT1 dysregulation as a common feature of aplastic anemia","volume":"3","author":"Rosenberg","year":"2022","journal-title":"Med (N Y)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501739","article-title":"Memory stem T cells in autoimmune disease: High frequency of circulating CD8+Memory stem cells in acquired aplastic anemia","volume":"196","author":"Hosokawa","year":"2016","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-717140","article-title":"Pure red cell aplasia","volume":"128","author":"Means","year":"2016","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018022723","article-title":"Frequent STAT3 mutations in CD8(+) T cells from patients with pure red cell aplasia","volume":"2","author":"Kawakami","year":"2018","journal-title":"Blood Adv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-315218","article-title":"Chronic IFN-\u03b3 production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1\/PU.1 axis","volume":"118","author":"Libregts","year":"2011","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06220.x","article-title":"Type I interferonopathies: a novel set of inborn errors of immunity","volume":"1238","author":"Crow","year":"2011","journal-title":"Ann N Y Acad Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.928213\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T01:17:41Z","timestamp":1661735861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.928213\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2022.928213"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.928213","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]},"article-number":"928213"}}